 "The pink of health: Trade generics now key growth driver for Cipla")
Mumbai-headquartered Cipla’s trade generics business clocked a compound annual growth rate (CAGR) of 25 per cent over FY18-FY22. Its branded prescription business, on the other hand, clocked a 10 per cent CAGR during the same period.
Trade generics are drugs that are pushed directly to trade and not promoted via doctors.
Cipla’s India business posted a 13 per cent CAGR over the FY18-22 period; the branded generics business accounted for 80 per cent of its total business in the country. In FY22, the India business of Cipla clocked 27 per cent year-on-year growth to Rs 980 crore.
